Aberdeen Group plc Buys 86,314 Shares of Sanofi $SNY

Aberdeen Group plc lifted its stake in shares of Sanofi (NASDAQ:SNY) by 22.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 467,241 shares of the company’s stock after acquiring an additional 86,314 shares during the quarter. Aberdeen Group plc’s holdings in Sanofi were worth $22,642,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the business. Financial Consulate Inc. purchased a new stake in shares of Sanofi during the 3rd quarter worth $26,000. Measured Wealth Private Client Group LLC purchased a new stake in Sanofi in the third quarter valued at approximately $29,000. Palisade Asset Management LLC acquired a new stake in shares of Sanofi in the third quarter worth $30,000. First Horizon Corp purchased a new stake in shares of Sanofi in the third quarter worth about $33,000. Finally, Salomon & Ludwin LLC lifted its stake in shares of Sanofi by 1,046.3% in the 3rd quarter. Salomon & Ludwin LLC now owns 768 shares of the company’s stock valued at $39,000 after purchasing an additional 701 shares during the period. 14.03% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on SNY. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating on shares of Sanofi in a research report on Friday, January 16th. Barclays lowered shares of Sanofi from an “overweight” rating to an “equal weight” rating in a report on Tuesday, January 6th. Guggenheim lowered shares of Sanofi from a “buy” rating to a “neutral” rating in a research note on Tuesday, December 9th. Sanford C. Bernstein raised Sanofi to a “strong-buy” rating in a research report on Thursday, March 19th. Finally, Citigroup initiated coverage on Sanofi in a report on Tuesday, January 27th. They issued a “neutral” rating for the company. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $61.50.

Sanofi Price Performance

SNY stock opened at $47.89 on Monday. Sanofi has a twelve month low of $43.32 and a twelve month high of $55.77. The company has a current ratio of 1.09, a quick ratio of 0.73 and a debt-to-equity ratio of 0.20. The business has a 50 day simple moving average of $46.44 and a 200-day simple moving average of $48.02. The company has a market capitalization of $116.80 billion, a P/E ratio of 13.30, a PEG ratio of 1.19 and a beta of 0.42.

About Sanofi

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.